期刊文献+

甲硝唑固体分散体的制备及痤疮洗剂的质量改进

Preparation of Acne Lotion Containing A Metronidazole Solid Dispersion Formulation
下载PDF
导出
摘要 目的制备甲硝唑固体分散体并建立其中甲硝唑的含量测定方法,将该固体分散体作为制备痤疮洗剂的中间体,以提高原有洗剂当中甲硝唑的溶解度。方法分别以聚乙二醇10000、聚乙二醇6000为载体,采用熔融法制备了甲硝唑固体分散体,进行X-射线粉末衍射分析以鉴别药物在不同载体中的分散状态,比较筛选出形成固体分散体的理想载体材料并制备固体分散体洗剂,采用紫外分光光度法,检测波长为316.0nm,测定固体分散体以及洗剂当中甲硝唑的含量。结果甲硝唑以无定型状态存于聚乙二醇10000中,而以晶体形式存在于聚乙二醇6000中,甲硝唑-聚乙二醇10000固体分散体洗剂为澄清溶液,甲硝唑浓度在5~13μg/mL范围内与吸光度呈良好线性关系(r=0.9999),平均回收率为99.76%,RSD为0.14%(n=9)。结论熔融法成功制备了甲硝唑-聚乙二醇10000固体分散体,制备工艺简单易行、成本较低,固体分散技术能够显著提高甲硝唑的溶解度和制剂的稳定性,含量测定方法稳定、快速、准确、简便,可以作为甲硝唑-聚乙二醇10000固体分散体以及痤疮洗剂中甲硝唑的质量控制方法。 Objective To prepare metronidazole solid dispersion; to establish a method for the determination of metronidazole in the solid dispersion; to use the solid dispersion as an intermediate to prepare acne lotion for improving the dissolubility of metronidazole in the previous lotion. Methods Metronidazole solid dispersions were prepared with PEG10 000 and PEG6 000 as carriers by melting method respectively. Powder X-ray diffractometry was used to identify the state of the drug in the 2 carriers. The most ideal carrier was used to prepare solid dispersion lotion. Ultraviolet spectrometry was used to measure the content of metronidazole in the solid dispersion and the lotion with detective wavelength at 316.0 nm. Results Metronidazole was dispersed amorphously in PEG10 000 but existed as crystal in PEG6 000. The improved lotion was plained solution. The calibration curve was linear in the range of 5 - 13 p.g/mL ( r = 0. 999 9 ) for metronidazole. The average recovery was 99.76 % with RSD 0.14% (n = 9). Conclusion Metronidazole-PEGl0 000 sohd dispersion has been prepared successfully by melting method. The procedure is simple, available and economic. The technology of solid dispersion is potent in improving the dissolution of metronidazole and the stability of the lotion. The UV method is reproducible, rapid, accurate, simple, and is suitable for the quality control of metronidazole in the PEG10 000 solid dispersion and ache lotion.
出处 《今日药学》 CAS 2013年第11期712-716,共5页 Pharmacy Today
基金 新疆医科大学科研创新基金项目(编号:XJC201249)
关键词 甲硝唑 固体分散体 聚乙二醇 痤疮洗剂 紫外分光光度法 metronidazole solid dispersion PEG acne lotion ultraviolet spectrometry
  • 相关文献

参考文献10

  • 1郭喆霏,黎永诚,刘旭,陆明,吴传斌.二氟尼柳固体分散体的制备工艺研究及质量评价[J].广东药学院学报,2013,29(4):357-362. 被引量:3
  • 2林以宁,赵浩如,蔡晓翠.黄芩苷不同给药载体的巴布剂的制备及体外透皮性能[J].中国医院药学杂志,2010,30(21):1855-1857. 被引量:11
  • 3Khalil Sakeer,Hind Al-Zein,Issa Hassan,Sandip Desai,Ali Nokhodchi.Enhancement of dissolution of nystatin from buccoadhesive tablets containing various surfactants and a solid dispersion formulation[J].Archives of Pharmacal Research.2010(11)
  • 4Gerrit S. Zijlstra,Michiel Rijkeboer,Dirk Jan Drooge,Marc Sutter,Wim Jiskoot,Marco Weert,Wouter L. J. Hinrichs,Henderik W. Frijlink.Characterization of a cyclosporine solid dispersion for inhalation[J].The AAPS Journal.2007(2)
  • 5Christian Leuner,Jennifer Dressman.Improving drug solubility for oral delivery using solid dispersions[J].European Journal of Pharmaceutics and Biopharmaceutics.2000(1)
  • 6Sang-Chul Shin,Cheong-Weon Cho,In-Joon Oh.Enhanced efficacy by percutaneous absorption of piroxicam from the poloxamer gel in rats[J].International Journal of Pharmaceutics.2000(2)
  • 7Sang-Chul Shin,Cheong-Weon Cho,Hoo-Kyun Choi.Permeation of Piroxicam from the Poloxamer Gels[J].Drug Development and Industrial Pharmacy.1999(3)
  • 8Sang-Chul Shin,Cheong-Weon Cho.Physicochemical Characterizations of Piroxicam-Poloxamer Solid Dispersion[J].Pharmaceutical Development and Technology.1997(4)
  • 9Schmadel LK,McEvoy GK.Topical metronidazole: a new therapy for rosacea[].Clinical Pharmacy.1990
  • 10Gruber,D. M.,Sator,M. O.,Joura,E. A.,Kokoschka,E. M.,Heinze,G.,Huber,J. C.Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial[].Archives of Dermatology.1998

二级参考文献22

  • 1李颖,潘卫三,陈士林,杨大坚,陈新滋,徐宏喜.葛根素磷脂复合物的制备及其固体分散体研究[J].中国药学杂志,2006,41(15):1162-1167. 被引量:41
  • 2ALBERS J,ALLES R,MATTH K,et al.Mechanism of drug release from polymethacrylate-based extrudates and milled strands prepared by hot-melt extrusion[J].Eur J Pharm Biopharm,2009,71(2):387-394.
  • 3SUWARDIE H,WANG PENG,TODD D B,et al.Rheological study of the mixture of acetaminophen and polyethylene oxide for hot-melt extrusion application[J].Eur J Pharm Biopharm,2011,78(3):506-512.
  • 4FRANK K J,ROSENBLATT K M,WESTEDT U,et al.Amorphous solid dispersion enhances permeation of poorly soluble ABT-102:True supersaturation vs.apparent solubility enhancement[J].Int J Pharm,2012,437(1/2):288-293.
  • 5BREITENBACH J.Melt extrusion:from process to drug delivery technology[J].Eur J Pharm Biopharm,2002,54(2):107-117.
  • 6REPKA M A,BATTU S K,UPADHYE S B,et al.Pharmaceutical applications of hot-melt extrusion:Part Ⅱ[J].Drug Dev Ind Pharm,2007,33(10):1043-1057.
  • 7DINUNZIO J C,BROUGH C,HUGHEY J R,et al.Fusion production of solid dispersions containing a heat-sensitive active ingredient by hot melt extrusion and Kinetisol dispersing[J].Eur J Pharm Biopharm,2010,74(2):340-351.
  • 8MART(I)NEZ-OHARRIZ M C,RODR(I)GUEZ-ESPINOSA C,MART(I)NC,et al.Solid dispersions of diflunisal-PVP:Polymorphic and amorphous states of the drug[J].Drug Dev Ind Pharm,2002,28(6):717-725.
  • 9MARSAC P,LI T,TAYLOR L.Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters[J].Pharm Res,2009,26(1):139-151.
  • 10TAYLOR L,ZOGRAFI G.Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions[J].Pharm Res,1997,14(12):1691-1698.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部